Protagonist Therapeutics Inc (PTGX)

Aug 19, 2025

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Newport Daily News

Aug 19, 2025

Aug 18, 2025

Protagonist Therapeutics Inc. Stock Lags Behind Sector Benchmarks2025 Macro Impact & High Conviction Buy Zone Picks - newsyoung.net

Aug 18, 2025

Aug 15, 2025

STATE STREET CORP's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Aug 15, 2025

Aug 14, 2025

Protagonist (PTGX) Q2 Revenue Falls 26% - AOL.com

Aug 14, 2025

Aug 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates - 富途牛牛

Aug 14, 2025

Aug 14, 2025

Protagonist Therapeutics Inc. Approaches Psychological Resistance LevelQuarterly Profit Report & Weekly Hot Stock Watchlists - thegnnews.com

Aug 14, 2025

Aug 14, 2025

Protagonist Therapeutics’ SWOT analysis: biotech firm’s stock poised for growth - Investing.com Canada

Aug 14, 2025

Aug 12, 2025

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Aug 12, 2025

Aug 12, 2025

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? - Yahoo Finance

Aug 12, 2025

Aug 11, 2025

Protagonist Therapeutics shares rise 3.78% intraday amid global geopolitical tensions. - AInvest

Aug 11, 2025

Aug 11, 2025

Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail

Aug 11, 2025

Aug 10, 2025

Citi Analyst Maintains Buy Rating on Protagonist Therapeutics with $72.00 Price Target - AInvest

Aug 10, 2025

Aug 08, 2025

Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks

Aug 08, 2025

Aug 07, 2025

Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera - TipRanks

Aug 07, 2025

Aug 07, 2025

Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment - TipRanks

Aug 07, 2025

Aug 07, 2025

Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability - TipRanks

Aug 07, 2025

Aug 07, 2025

Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP - TipRanks

Aug 07, 2025

Aug 07, 2025

Protagonist Therapeutics stock price target raised to $69 by JMP - Investing.com Canada

Aug 07, 2025

Aug 07, 2025

Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress - TipRanks

Aug 07, 2025

Aug 07, 2025

Protagonist (PTGX) Q2 Revenue Falls 26% - The Motley Fool

Aug 07, 2025

Aug 07, 2025

Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus

Aug 07, 2025

Aug 07, 2025

Protagonist Therapeutics: Q2 Earnings Snapshot - Connecticut Post

Aug 07, 2025

Aug 06, 2025

Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating - TipRanks

Aug 06, 2025

Aug 06, 2025

Protagonist Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada

Aug 06, 2025

Aug 06, 2025

Why Protagonist Therapeutics Shares Are Dropping - TipRanks

Aug 06, 2025

Aug 06, 2025

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 06, 2025

Aug 06, 2025

Protagonist Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2025

Aug 06, 2025

Protagonist Therapeutics Q2 net loss beats expectations - MarketScreener

Aug 06, 2025

Aug 06, 2025

Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus - TipRanks

Aug 06, 2025

Aug 06, 2025

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - MSN

Aug 06, 2025

Aug 04, 2025

Does Protagonist Therapeutics Inc. stock pay reliable dividendsHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru

Aug 04, 2025

Aug 03, 2025

Why is Protagonist Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What drives Protagonist Therapeutics Inc. stock priceHigh-octane financial growth - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Does Protagonist Therapeutics Inc. stock perform well during market downturnsFree Stock Index Interpretation - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What is Protagonist Therapeutics Inc. company’s growth strategyRapid return acceleration - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is it the right time to buy Protagonist Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What is the dividend policy of Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is Protagonist Therapeutics Inc. a growth stock or a value stockTremendous return on equity - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What are the technical indicators suggesting about Protagonist Therapeutics Inc.Build wealth steadily with proven investment strategies - Jammu Links News

Aug 03, 2025

Aug 03, 2025

How does Protagonist Therapeutics Inc. compare to its industry peersHigh-octane investment gains - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Superior return velocity - Jammu Links News

Aug 03, 2025

Aug 03, 2025

How strong is Protagonist Therapeutics Inc. company’s balance sheetInvest confidently with professional market insights - Jammu Links News

Aug 03, 2025

Aug 02, 2025

Protagonist Therapeutics Inc. Stock Analysis and ForecastTriple-digit growth rates - Jammu Links News

Aug 02, 2025